FDA Moves to Make NAC Supplements Legal Again
21 November 2026, Silver Spring, US: The US Food and Drug Administration has proposed a rule that would let N-acetylcysteine (NAC), a widely used antioxidant ingredient, be sold lawfully as a dietary supplement, reversing the agency’s position of four years ago that NAC products could not be supplements at all. The agency announced the proposal on November 16 through its Human Foods Program, and it will be open for public comment for 60 days after publication in the Federal Register.
NAC is a modified form of cysteine, an amino acid the body uses to make glutathione, one of its main internal antioxidants. It is used in hospitals as a medicine, most notably to treat acetaminophen (paracetamol) overdose, and it is also sold in capsule and powder form by supplement makers, who market it for respiratory, liver and general antioxidant support. The FDA said such products have been on US shelves for more than 30 years and that, in reviewing the issue, it did not identify any safety concerns with NAC used in or as a dietary supplement.
How the rule would work
The legal problem for NAC stems from a clause in US food and drug law known as the drug exclusion provision. Under that clause, an ingredient that was approved as a drug before it was ever marketed as a food or supplement cannot later be sold as a dietary supplement. FDA relied on that reasoning in March 2022, when it responded to two citizen petitions from supplement trade groups and concluded that NAC-containing products cannot be dietary supplements.
The same law also gives FDA authority to issue a regulation declaring that a particular ingredient is not excluded, provided it finds that marketing it as a supplement would be lawful. The new proposal uses that power for the first time. It would create a new regulation titled “Dietary Ingredients Not Excluded from the Dietary Supplement Definition,” with NAC as the first ingredient on the list. Once finalized, NAC products could be marketed as supplements so long as they meet the rest of the Federal Food, Drug, and Cosmetic Act, including rules on labelling, manufacturing practices and the ban on disease treatment claims.
The rule does not change NAC’s status as a drug ingredient, and it does not approve any health claim. Supplement labels would still be limited to structure and function statements, such as describing a role in antioxidant activity, rather than claims to treat or prevent a disease.
Four years of enforcement discretion
In practice, NAC never fully left the market. In August 2022 FDA issued final guidance saying it would use enforcement discretion, a decision not to take action against certain NAC products labelled as dietary supplements, while it considered a longer-term solution. The agency said it intends to keep that discretion in place throughout the rulemaking process, so products now on sale are not expected to be affected while the proposal is under review.
The 2022 position had left manufacturers, ingredient suppliers and retailers uncertain about whether to keep producing and stocking an ingredient that regulators had said was not a lawful supplement, even as enforcement was paused.
FDA framed the new proposal as a deregulatory action under Executive Order 14192, “Unleashing Prosperity Through Deregulation,” which directs federal agencies to reduce regulatory burdens. The document has been filed with the Federal Register under document number 2026-23351, titled “Rulemaking to Provide that N-acetyl-L-cysteine Is Not Excluded from the Dietary Supplement Definition.”
The decision may also matter beyond NAC. Because this is the first time FDA has used its rulemaking power under the exclusion provision, the new regulation creates a list that could, in principle, take other ingredients in future. Several other compounds that have been caught between drug and supplement status, including some that were first studied or approved as medicines, have faced similar legal questions.
FDA said that once the rule is published, comments can be submitted for 60 days, after which the agency will review the responses before deciding whether to issue a final rule. The proposal does not set a date for a final decision.
Also Read: €2.9BN Invested in Biopesticide Innovation, but EU Farmers Still Face Long Waits for New Solutions
Global Agriculture is an independent international media platform covering agri-business, policy, technology, and sustainability. For editorial collaborations, thought leadership, and strategic communications, write to pr@global-agriculture.com







